Oryzon Genomics S.A. (ORY.MC)

EUR 2.74

(-0.36%)

Long Term Debt Summary of Oryzon Genomics S.A.

  • Oryzon Genomics S.A.'s latest annual long term debt in 2023 was 3.45 Million EUR , down -51.13% from previous year.
  • Oryzon Genomics S.A.'s latest quarterly long term debt in 2024 Q3 was - EUR , down -100.0% from previous quarter.
  • Oryzon Genomics S.A. reported annual long term debt of 7.06 Million EUR in 2022, down -31.76% from previous year.
  • Oryzon Genomics S.A. reported annual long term debt of 10.34 Million EUR in 2021, up 95.15% from previous year.
  • Oryzon Genomics S.A. reported quarterly long term debt of - EUR for 2024 Q3, down -100.0% from previous quarter.
  • Oryzon Genomics S.A. reported quarterly long term debt of 3.19 Million EUR for 2024 Q2, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Oryzon Genomics S.A. (2023 - 2019)

Historical Annual Long Term Debt of Oryzon Genomics S.A. (2023 - 2019)

Year Long Term Debt Long Term Debt Growth
2023 3.45 Million EUR -51.13%
2022 7.06 Million EUR -31.76%
2021 10.34 Million EUR 95.15%
2020 5.3 Million EUR 0.0%
2019 - EUR 0.0%

Peer Long Term Debt Comparison of Oryzon Genomics S.A.

Name Long Term Debt Long Term Debt Difference
Atrys Health, S.A. 162.72 Million EUR 97.879%
Biotechnologies Assets SA 5.15 Million EUR 33.052%
Pharma Mar, S.A. 27.03 Million EUR 87.237%
Laboratorios Farmaceuticos Rovi, S.A. 52.24 Million EUR 93.395%